Corporate Profile

AUM Biosciences is a global clinical-stage biotech company, focused on discovering, developing and advancing a pipeline of precision oncology therapeutics designed to deploy multi-faceted inhibition strategies to reverse cancer resistance. The company’s lead program, AUM has an extensive track record of selecting distinctive early-stage assets, successfully exiting virtual biotecl models, and has contributed significantly to the development of several currently marketed oncology treatments with annual peak sales up to $3B. AUM001, is a best-in-class MNK inhibitor targeting MSS Colorectal Cancer and many other tumor types by selective inhibition of oncogenic protein translation. The company has a portfolio of assets with clear de-risking mechanisms put in place.

Events

29 – 31st March 2022

Next Generation Kinase Inhibitor Summit 2022

Read more..

18 November 2021


Bio Connections Australia 2021

Read more..


25 August 2021

PI3K Pathways Virtual Summit 2021

Read more..


12 August 2021

Bio Connections Australia 2021

Read more..

Press Release

– AUM Biosciences Announces FDA IND Authorization for Global Phase 2 Trial of Selection Translation Inhibitor AUM001 in Colorectal Cancer

Read more..

– AUM Biosciences Appoints an industry veteran, Scott Jordan as Head of Corporate Development

Read more..

– AUM Biosciences Enters into Collaboration with Roche for Clinical Development of AUM001 in Combination with anti-PD-L1 Therapy in Solid Tumor Indications

Read more..